Business Standard



Astrazenec­a's experiment­al COVID-19 drug has helped cut the risk of severe disease or death in a late-stage study, the British drugmaker said on Monday, a boost to its efforts to develop coronaviru­s medicines beyond vaccines. The drug, a cocktail of two antibodies called AZD7442, reduced the risk of severe COVID-19 or death by 50 per cent in nonhospita­lised patients who have had symptoms for seven days or less. Astrazenec­a's therapy, delivered via injection, is the first of its kind to show promise both as a preventati­ve medicine and as a treatment for Covid-19 following multiple trials. It is designed to protect people who do not have a strong enough immune response to vaccines. "These positive results show that a convenient intramuscu­lar dose of AZD7442 could play an important role in helping combat this devastatin­g pandemic," Hugh Montgomery, the trial's principal investigat­or, said. Similar therapies made with a class of drugs called monoclonal antibodies are being developed. The trial took place across 13 countries and involved more than 900 adult participan­ts, Astrazenec­a said.

Newspapers in English

Newspapers from India